key: cord-0046438-dr3rojlh authors: Previtali, Giulia; Seghezzi, Michela; Moioli, Valentina; Sonzogni, Aurelio; Cerutti, Lorenzo; Marozzi, Roberto; Ravasio, Rudi; Gianatti, Andrea; Guerra, Giovanni; Alessio, Maria Grazia title: The pathogenesis of thromboembolic disease in covid-19 patients: Could be a catastrophic antiphospholipid syndrome? date: 2020-06-27 journal: Thromb Res DOI: 10.1016/j.thromres.2020.06.042 sha: 64d62cc3db22f2cd31a2b6b6553d70b0a413d131 doc_id: 46438 cord_uid: dr3rojlh nan J o u r n a l P r e -p r o o f 2 In December 2019 an epidemic of pneumonia caused by SARS-CoV-2, a novel coronavirus, developed from Wuhan, China [1] . The outbreak rapidly spread all over the world and the World Health Organization (WHO) declared the SARS-CoV-2 disease (named COVID-19) a pandemic on 11 th March 2020. About 15-20% of infected patients can develop interstitial pneumonia with alveolar damage and severe Acute Respiratory Distress Syndrome (ARDS), leading in 5% of cases to death [1] . The most severe patients need intensive care and show an increased risk of thromboembolic events, caused by an hyperinflammatory response targeting endothelium and leading to a pro-coagulation state, worsened by hypoxia and prolonged immobilization. These patients can develop pulmonary thrombosis and/or multiorgan failure due to thrombotic microangiopathy [2] . Although some patients meet the diagnostic criteria for the Disseminated Intravascular Coagulation (DIC) [3] , there is a group of COVID 19 severely ill patients in which the pathogenesis of the diffuse thrombotic status remains unclear. The Catastrophic Antiphospholipid Syndrome (CAPS) is a rare, life-threatening condition characterized by multiple thrombosis, affecting mainly small vessels and involving three or more organs, developing in less than a week, and associated with persistent antiphospholipid antibodies (aPL) positivity [4] . Peculiarly CAPS is triggered by precipitating factors and infections, mainly in respiratory tract, are the most frequent events [5] . The clinical course and the autopsy findings of 75 patients died for COVID-19 at Papa Giovanni XXIII Hospital in Bergamo between 19 th March and 09 th April 2020 suggest that some patients may have developed CAPS and we evaluate the presence of serum aPL to confirm the diagnosis. coagulation profile was assessed on CS-5100 System (Sysmex, Japan), using the manufacturer cut-offs. The study was conducted in accordance with the Helsinki Declaration and under the terms of all relevant local legislations. Study approval was obtained from the local ethical committee. The demographic characteristics of enrolled patients are summarized in Table 1 . The clinical and historical data were available for 29 patients. 24/29 (82.8%) had one or more comorbidities. Three patients (10.3%) were previously diagnosed for autoimmune diseases (two Rheumatoid Arthritis and one Hashimoto Thyroiditis); only one patient was previously treated with oral anticoagulant and seven patients with antiplatelet therapy. All the patients, but one, were treated for COVID-19 infection with a standard therapy composed by antibiotics, hydroxychloroquine and antiretroviral drugs; in addition, six patients also received prednisone; 13 patients undergone a treatment with low molecular weight heparin (LMWH). A patient died before starting of therapy. Laboratory features and aPL testing are showed in Table 2 Lactate dehydrogenase, C reactive protein and interleukin-6 were markedly increased in all patients, except for one with slightly increased value for interleukin-6 alone, indicating an hyperinflammatory state. The coagulation tests showed that all but one patient had increased value for D-Dimer, and in 12/32 patients (38.7%) the value was over 10000 ng/ml; prothrombin time (PT-INR) and activate thromboplastin time were generally normal or slightly prolonged. Fibrinogen test was performed only in 17/35 patients, with increased values in 9/17(52.9%) but reduced in one. 32/35 (91.4%) patients had evidence of kidney and/or hearth and/or liver damage. The thromboembolic disease in COVID 19 could have a multifactorial pathogenesis, [6] . Hypoxia and prolonged immobilization are important factors, but the diffuse inflammatory state and the resulting "cytokine storm" seems to be the main triggers. The autopsies that have been conducted at Papa Giovanni XXIII Hospital in Bergamo, highlighted thrombotic damages in several organs. Several diseases such as DIC, sepsis, macrophage activated syndrome (MAS) and CAPS could be the underlying causes of such damages [4] . Recently some authors have been evidenced that the most COVID-19 patients meet the diagnostic criteria for DIC [7] ; in our cohort, the appropriate assays and information were available for 17 (48.6%) patients and only six (17.1%) meet the DIC criteria: platelet count and PT-INR were almost normal and fibrinogen values, when tested, were increased, possibly reflecting the hyperinflammation state; none of our patients except one showed hemorrhages and the histological findings consisting with both microvascular and macrovascular thrombosis did not fit with classical morphological features of DIC. Likewise, none of our patients fulfilled sepsis clinical criteria and the histological post-mortem findings were not consistent with this assumption. For macrophage activated syndrome, Carsana et al. [8] reported the presence of mainly monocyte/macrophage infiltration in lung biopsies of COVID-19 patients but normal platelet count, high level of fibrinogen and absence of hepato-and splenomegaly in our cohort of patients, exclude also this hypothesis. To the best of our knowledge, the presence of antiphospholipid antibodies in literature are reported only in three Chinese patients with multiple brain infarcts revealed with imaging techniques [9] . Our patients fulfilled the main clinical diagnostic criteria for CAPS [4] : evidence of involvement in three or more organs; development of manifestations simultaneously or in less than a week, confirmation by histopathology of small vessel occlusion in at least one organ. Based on these findings, to meet all the diagnostic criteria of CAPS, it was necessary to demonstrate the presence of aPL [5] . Unfortunately, in our cohort almost all the patients were negative for the aPL profile tested. Only 6/35 (17.1%) patients showed very low and not relevant antibodies levels but it is reported that slightly and transient increase of aPLs could be a common finding during any kind of infectious, whereas CAPS is always characterized by very high levels of autoantibodies [4] . Three conventional aPL markers are described in literature and used to diagnose CAPS: ACA, β2GPI and Lupus Anticoagulant (LAC). The main limit of our work it is that our patients were not tested for LAC due to the lack of plasma samples. It is reported in literature a very high concordance between LAC and PS/PT testing and Litvinova et al. [10] reported that all CAPS patients are positive for both IgG and IgM PS/PT but only three of our patients were slightly positive for these tests. In particular, one out of two patients, found positive for PS/PT IgM was previously diagnosed with Hashimoto thyroiditis and was also positive for myeloperoxidase antibodies, thus suggesting a general activation of the immune system in an autoimmune-predisposed patient. J o u r n a l P r e -p r o o f Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Towards a definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation Catastrophic APS in the context of other thrombotic microangiopathies Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Anticoagulant treatment is associated with decreased mortality in coronavirus disease 2019 patients with coagulopathy Pulmonary post-mortem findings in a large series of COVID-19 cases from Northern Italy Coagulopathy and antiphospholipid antibodies in CRP >1 mg/dL